Comparison 8. PERPHENAZINE vs CLOCAPRAMINE.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Leaving the study early: 1. Any reason	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
1.1 short term	1	192	Risk Ratio (M‐H, Random, 95% CI)	1.40 [0.59, 3.34]
2 Leaving the study early: 2. Due to adverse events	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
2.1 short term	1	192	Risk Ratio (M‐H, Random, 95% CI)	0.61 [0.15, 2.49]
3 Leaving the study early: 3. Due to relapse / worsening or no improvement	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
3.1 short term	1	192	Risk Ratio (M‐H, Random, 95% CI)	2.38 [0.63, 8.94]
4 Global state: 1. Change over time ‐ no better or deterioration (ITT)	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
4.1 short term	1	192	Risk Ratio (M‐H, Random, 95% CI)	1.15 [0.88, 1.49]
5 Adverse events: Movement disorders	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
5.1 akathisia ‐ short term	1	192	Risk Ratio (M‐H, Random, 95% CI)	0.84 [0.49, 1.44]
5.2 ataxia ‐ short term	1	192	Risk Ratio (M‐H, Random, 95% CI)	0.34 [0.04, 3.21]
5.3 dyskinesia ‐ short term	1	192	Risk Ratio (M‐H, Random, 95% CI)	0.57 [0.20, 1.63]
5.4 parkinsonism ‐ short term	1	192	Risk Ratio (M‐H, Random, 95% CI)	0.98 [0.60, 1.59]
5.5 use of antiparkinsonian drugs ‐ short term	1	192	Risk Ratio (M‐H, Random, 95% CI)	0.88 [0.69, 1.13]
6 Other adverse events: 1. Anticholinergic	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
6.1 blurred vision ‐ short term	1	192	Risk Ratio (M‐H, Random, 95% CI)	0.41 [0.08, 2.05]
6.2 dry mouth ‐ short term	1	192	Risk Ratio (M‐H, Random, 95% CI)	0.68 [0.25, 1.84]
7 Other adverse events: 2. Arousal	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
7.1 insomnia ‐ short term	1	192	Risk Ratio (M‐H, Random, 95% CI)	1.16 [0.83, 1.63]
7.2 need of additional benzodiazepines ‐ short term	1	192	Risk Ratio (M‐H, Random, 95% CI)	1.09 [0.81, 1.46]
7.3 sleepiness/sedation ‐ short term	1	192	Risk Ratio (M‐H, Random, 95% CI)	1.02 [0.47, 2.24]
8 Other adverse events: 3. At least one	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
8.1 short term	1	192	Risk Ratio (M‐H, Random, 95% CI)	0.92 [0.78, 1.07]
9 Other adverse events: 4. Cardiovascular	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
9.1 angina pectoris ‐ short term	1	192	Risk Ratio (M‐H, Random, 95% CI)	0.68 [0.20, 2.34]
9.2 palpitations ‐ short term	1	192	Risk Ratio (M‐H, Random, 95% CI)	0.34 [0.07, 1.64]
10 Other adverse events: 5. Central nervous system	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
10.1 disturbance of consciousness ‐ short term	1	192	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
10.2 headache ‐ short term	1	192	Risk Ratio (M‐H, Random, 95% CI)	2.55 [0.83, 7.86]
10.3 paraesthesia ‐ short term	1	192	Risk Ratio (M‐H, Random, 95% CI)	4.08 [0.46, 35.88]
10.4 vertigo ‐ short term	1	192	Risk Ratio (M‐H, Random, 95% CI)	1.02 [0.45, 2.34]
11 Other adverse events: 6. Gastrointestinal	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
11.1 constipation ‐ short term	1	192	Risk Ratio (M‐H, Random, 95% CI)	1.25 [0.54, 2.87]
11.2 icterus ‐ short term	1	192	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
11.3 loss of appetite ‐ short term	1	192	Risk Ratio (M‐H, Random, 95% CI)	1.76 [0.89, 3.50]
11.4 nausea and vomiting ‐ short term	1	192	Risk Ratio (M‐H, Random, 95% CI)	2.30 [1.05, 5.03]
12 Other adverse events: 7. Skin	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
12.1 pruritus ‐ short term	1	192	Risk Ratio (M‐H, Random, 95% CI)	1.02 [0.15, 7.10]
12.2 rash ‐ short term	1	192	Risk Ratio (M‐H, Random, 95% CI)	1.02 [0.15, 7.10]
13 Other adverse events: 8. Genitourinary	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
13.1 diminished sexual desire	1	192	Risk Ratio (M‐H, Random, 95% CI)	1.02 [0.06, 16.09]
13.2 micturition disturbances ‐ short term	1	192	Risk Ratio (M‐H, Random, 95% CI)	0.51 [0.10, 2.72]
14 Other adverse events: 9. Others	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
14.1 cramps ‐ short term	1	192	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
14.2 sweating ‐ short term	1	192	Risk Ratio (M‐H, Random, 95% CI)	0.17 [0.02, 1.39]